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Background: Generic epidemiological differences between extended-spectrum beta-lactamase (ESBL)-producing
Escherichia coli (ESBL-EC) and Klebsiella pneumoniae (ESBL-KP), are poorly defined. Nonetheless, defining such differences
and understanding their basis could have strategic implications for infection control policy and practice.
Methods: Between 2009 and 2011 patients with bacteraemia due to ESBL-EC or ESBL-KP across all three acute hospitals
in the city of Auckland, New Zealand, were eligible for inclusion. Recognised risk factors for ESBL bacteraemia were
compared between species in a retrospective case-case study design using multivariate logistic regression. Representative
isolates underwent ESBL gene characterisation and molecular typing.
Results: 170 patients and 176 isolates were included in the study (92 patients with ESBL-EC, 78 with ESBL-KP). 92.6% had
CTX-Ms. 39% of EC were ST131 while 51% of KP belonged to 3 different STs (i.e. ST20, ST48 & ST1087). Specific sequence
types were associated with specific hospitals for ESBL-KP but not ESBL-EC. Variables positively associated with ESBL-EC on
multivariate analysis were: community acquired infection (odds ratio [OR] 7.9; 95% CI: 2.6-23.9); chronic pulmonary disease
(OR 5.5; 95% CI: 1.5-20.1); and high prevalence country of origin (OR 4.3; 95% CI: 1.6-11.6). Variables negatively associated
with ESBL-EC were previous transplant (OR 0.06; 95% CI: 0.007-0.6); Hospital 2 (OR 0.3; 95% CI: 0.1-0.7) and recent ICU
admission (OR 0.3; 95% CI: 0.07-0.9).
Conclusions: Differences in risk profiles between patients with ESBL-EC and ESBL-KP suggest fundamental differences in
transmission dynamics. Understanding the biological basis for these differences could have implications for infection
control practice. Tailoring of infection control measures according to ESBL species may be indicated in some instances.
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The global dissemination of extended-spectrum β-
lactamase producing Enterobacteriaceae (ESBL-E) poses a
growing challenge to both public health and hospital in-
fection control services [1].Whereas early reports of
ESBL-E typically described hospital outbreaks of TEM and
SHV producing Klebsiella pneumoniae, over the last* Correspondence: JoshuaF@adhb.govt.nz
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unless otherwise stated.decade reports have focused on CTX-M, which has be-
come the overwhelmingly predominant ESBL subclass
worldwide [2]. The rise of CTX-M has been characterized
by increased rates of community transmission and an asso-
ciation with Escherichia coli. More recently however, large
epidemics of CTX-M producing K. pneumoniae have also
been reported [3-5]. Despite this development, few studies
to identify risk factors for ESBL-E have focused specifically
on K. pneumoniae. Although several studies have combined
different ESBL-E species together into single case groups
[6,7] most have focused exclusively on CTX-M producing
E. coli [8-10]. Moreover, while epidemiological differencesal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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guidelines [11], few studies have sought to systematic-
ally characterize and quantify these differences. Nonethe-
less, defining such differences and better understanding
their biological basis could have strategic implications for
policy and practice; both for community public health and
hospital infection control.
In view of this background, we sought to systematic-
ally identify and quantify differences in the risk factor
profiles between patients with ESBL-E. coli (ESBL-EC)
and ESBL-K. pneumoniae (ESBL-KP) bacteraemia over a
three year period.Methods
Study design/inclusion criteria
We performed a retrospective case-case study of patients
admitted to hospital with ESBL-E bacteraemia in the
Auckland region of New Zealand over a 3 year period in
order to identify and quantify differences in the risk fac-
tor profiles of patients with ESBL-EC and ESBL-KP bac-
teraemia. A 3 year period was chosen because it was
estimated that this would provide over 70 patients in
both the ESBL-EC and ESBL-KP groups, a number
which we speculated would allow for meaningful statis-
tical comparison between the two groups. The absence
of similar previous case-case comparisons precluded a
formal power calculation. All patients with blood culture
isolates of either ESBL-EC or ESBL-KP in Auckland,
New Zealand, between January 1st 2009 and December
31st 2011 were eligible for inclusion. All 3 public hospi-
tals providing acute medical care to the Auckland popu-
lation of approximately 1.4 million participated in the
study (in the Auckland region, all acute medical care is
provided by public hospitals). These 3 hospitals provide
a mix of tertiary and secondary care under medical and
surgical specialties and subspecialties, ranging in ap-
proximate size from 600–900 beds (Hospital 1–900 beds
[700 adult and 200 paediatric]; Hospital 2–800 beds [725
adult and 75 paediatric] and Hospital 3–600 beds [590
adult and 10 paediatric]). For the duration of the study,
laboratories at all 3 hospitals had a policy of routinely
stocking all isolates of ESBL-E from blood at −70°C.
Representative isolates were included for each patient
bacteraemia episode. For patients with multiple bacter-
aemia episodes with the same species, only the first epi-
sode was included. Patients with both ESBL-EC and
ESBL-KP simultaneously were excluded from the risk
factor analysis as were patients that had successive
bacteraemia episodes with each of the two species. Pa-
tients with no available isolate were also excluded.
Both paediatric and adult patients were eligible for in-
clusion. Approval was obtained from the Northern
Regional Ethics Committee.Patient data collection
Data were collected from the electronic medical records
by a single investigator. Because the hospitals involved in
the study provide healthcare to the entire Auckland re-
gion, complete and reliable data on the timing and num-
ber of admissions to hospital in the Auckland area were
available for all patients. Patient risk factors were broadly
divided into: 1) factors relating to acquisition (including
demographic characteristics), 2) source of bacteraemia, 3)
comorbidities.
Community-onset infection was defined as a positive
blood culture collected within the first 48 hours of hos-
pital admission. Community acquisition was defined ac-
cording to a modified version of the Friedman criteria [12]
and was ascribed to patients having all 4 of the following
characteristics: 1) no hospital admissions in the Auckland
region during the preceding year, 2) not a long term care
facility resident, 3) not a dialysis patient, 4) community-
onset infection. High prevalence regions were defined as
China, India, Pakistan, South America, Africa, the Middle
East and Southeast Asia [13,14]. Country of origin was
assigned on the basis of self reported ethnicity/country of
origin data recorded routinely on admission to hospitals
in the Auckland region. The designation of New Zealand
Maori or NZ European ethnicity was also made on the
basis of this data. Recent ICU admission was defined as
patients who had been admitted to ICU within the last
3 months, excluding the current admission. The source of
bacteraemia was determined through an assessment of the
clinical records and microbiology findings. Febrile neutro-
paenia was defined as bacteraemia with no clear primary
source in patients with fever and a neutrophil count of less
than 0.5 × 109/L. Gastrointestinal infections included intra-
abdominal gastrointestinal infections as well as infection
due to acute hepatobiliary obstruction. Central line infec-
tions were defined as bacteraemia in non-neutropaenic pa-
tients with a central line and no clear alternative primary
source. Prostate biopsy related infections were distin-
guished from other UTI by a history of a trans-rectal pros-
tate biopsy in the preceding 72 hours. Recurrent UTIs were
defined as a record of two or more previous admissions to
hospital with UTI or documented evidence of recurrent
UTI in the community. Patients were defined as having a
long term catheter if either a urethral or suprapubic cath-
eter was present on admission to hospital. Transplants in-
cluded both hematopoietic stem cell and solid organ.
Chronic pulmonary disease required documented evidence
of asthma, chronic obstructive airways disease or other
chronic respiratory diseases in the clinical records. Other
definitions were defined as per Charlson et al. [15].
Microbiology and molecular testing of isolates
Blood culture isolates of ESBL-E across all 3 laboratories
in the Auckland area are routinely frozen and stocked in
Table 1 Comparison of ESBL-EC and ESBL-KP with respect
to molecular characteristics and susceptibility profiles
ESBL-EC (%) ESBL-KP (%) P value
aac(6’)-Ib-cr 41/95 (43.1) 61/81 (75.3) <0.0001
qnrB 11/95 (11.6) 65/81 (80.2) <0.0001
blaCTX-M-15 58/95 (61.1) 70/81 (86.4) 0.0002
blaCTX-M-14 28/95 (29.5) 2/81 (2.5) <0.0001
blaTEM-1 53/95 (55.8) 20/81 (24.7) <0.0001
blaOXA 42/95 (44.2) 50/81 (61.7) 0.024
Other blaCTX-M 4/95 (4.2) 1/81 (1.2) 0.38
Non blaCTX-M ESBLs 5/95 (5.3) 8/81 (9.9) 0.26
Gentamicin NS 53/95 (55.8) 66/81 (81.5) 0.0003
Trimethoprim-
sulfamethoxazole NS
67/95 (70.5) 78/81 (96.3) <0.0001
Fluoroquinolone NS 66/95 (69.5) 62/81 (76.5) 0.31
NS ≥ 4 antibiotic classes 36/95 (37.9) 55/81 (67.9) <0.0001
NS, non-susceptible. Representative antibiotics for the three non-beta-lactam
antibiotic classes tested were: gentamicin; trimethoprim-sulfamethoxazole,
ciprofloxacin. All isolates were assumed by definition to be resistant
to cephalosporins.
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isolates were sub-cultured onto nutrient agar slopes prior
to molecular analysis. Susceptibility testing and ESBL
screening and confirmation tests were performed accord-
ing to the 2009 CLSI guidelines [16]. Isoelectric focusing
(IEF) was performed on freeze-thaw extracts as previously
described [17]. Polymerase chain reaction (PCR) amplifi-
cation and sequencing for blaCTX-Ms, blaOXAs, blaTEMs,
blaSHV, was carried out on the isolates with a GeneAmp
9700 ThermoCycler instrument (Applied Biosystems,
Norwalk, Con) using PCR conditions and primers as pre-
viously described [17]. Additional investigations included
PCR for plasmid-mediated quinolone resistance determi-
nants aac-(6’)-Ib-cr, qnr B, qnrA and qnrS [17].
Genetic relatedness was examined by pulsed-field gel
electrophoresis (PFGE) following extraction of genomic
DNA and digestion with XbaI using the E. coli (O157:H7)
protocol established by the Centers for Disease Control
and Prevention, Atlanta, GA [18]. Cluster designation was
based on isolates showing approximately 80% or greater
relatedness, which corresponds to the “possibly related
(4–6 bands difference)” criteria of Tenover et al. [19]. Multi-
locus sequence typing (MLST) was performed using stand-
ard protocols for E. coli (http://mlst.warwick.ac.uk/mlst/dbs/
Ecoli) and K. pneumoniae (http://www.pasteur.fr/recherche/
genopole/PF8/mlst/Kpneumoniae.html). MLST was per-
formed on pulsed field clusters consisting of ≥10 isolates.
Statistical analysis
The primary analysis involved using ESBL-EC bacteraemia
as the dependent variable and using patients with ESBL-
KP as a comparator group. For each potential risk factor,
odds ratios and 95% confidence intervals were calculated
using univariable logistic regression. Chi square test or
Fisher’s exact test and Wilcoxon rank sum tests were used
to compare categorical and continuous variables respect-
ively. Age, gender and hospital were considered eligible
for inclusion in a multivariate analysis on an a priori basis
along with demographic and comorbidity risk factor vari-
ables with a p value of less than 0.1. Underlying sources of
bacteraemia and the timing of infection (ie: community or
hospital onset) were excluded from the multivariate ana-
lysis because they occurred concurrently with the outcome
and were therefore not considered to be risk factors in the
conventional sense. The final model was derived using for-
ward logistic regression. All statistical testing was two
tailed and statistical significance was defined as P ≤ 0.05.
Statistical analyses were performed using SPSS software
(Version 21.0).
Results
Across all 3 sites during the study period there were a
total of 206 patients with bloodstream infections with
ESBL-EC and ESBL-KP (89, 57, and 60 from hospitals 1,2 and 3 respectively). Of these, 173 patients (84.0%) had
isolates available and were included in the study (33 pa-
tients were excluded due to not having an isolate available).
These 173 patients had a total of 176 isolates because two
patients had simultaneous bacteraemia with ESBL-EC and
ESBL-KP and one patient had successive bacteraemic epi-
sodes, firstly with ESBL-KP and then ESBL-EC over a year
later. These 3 patients were excluded from the risk factor
analysis. This left 170 patients for the risk factor analysis
[92 patients with ESBL-EC (54%) and 78 with ESBL-KP
(46%)]. The percentage of isolates available from each hos-
pital were 84/90 (93.3%) from Hospital 1; 57/59 (96.6%)
from Hospital 2 and 35/60 (58.3%) from Hospital 3. The
proportion with ESBL-EC among available isolates in each
hospital was 64.3% for Hospital 1; 40.4% for Hospital 2; and
51.4% for Hospital 3. Among excluded patients with no
available isolate, the proportion with ESBL-EC was 51%.
Overall CTX-M ESBLs accounted for 92.6% of the 176
isolates. CTX-M-15 predominated (72.7%). Of the ESBL-
EC, 29% produced CTX-M-14, 61% CTX-M-15 and 4%
TEM-52, while 1 each produced CTX-M-24, CTX-M-27
and SHV-12. Overall 39% belonged to ST131. Of the 81
ESBL-KP, 2% produced CTX-M-14, 86% CTX-M-15, 5%
SHV2a while 1 each produced SHV-12 and TEM-52.
ESBL-KP isolates were more likely than ESBL-EC to carry
fluoroquinolone resistance genes aac-(6’)-Ib-cr and qnrB
in combination (68% versus 10% respectively) but were
less likely to carry CTX-M-14 and TEM-1 (Table 1).
ESBL-KP had significantly higher rates of resistance to
gentamicin and trimethoprim-sulfamethoxazole as well as
higher rates of resistance to 4 or more antibiotic classes
(Table 1). Rates of fluoroquinolone resistance were similar.
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isolates per cluster) among ESBL-KP that were identified
by MLST as: ST20 (n = 15); ST48 (n = 13) and ST1087
(n = 13). ST1087 is a novel ST that produced CTX-M-15
in combination with OXA-1 and TEM-1 as well as aac
(6)-lb-cr and qnrB. It was also noted to be less suscep-
tible to ciprofloxacin (0/13 vs 18/68; p = 0.03) and to
cause higher rates of infection in febrile neutropaenic
patients than other ESBL-KP isolates (5/13 vs 7/68; p =
0.02). When community acquired isolates were excluded,
there was a significant association between ST48 and
Hospital 3 (7/15 vs 6/60; p = 0.003) as well as ST1087 and
Hospital 2 (10/32 vs 3/43; p = 0.01). ST20 was also more
common among patients from Hospital 2 although this
was not statistically significant (8/32 vs 5/43; p = 0.19).
PFGE identified 1 major cluster (i.e. 37/95 [38.9%]) among
the ESBL-EC that was identified as ST131. No significant
associations were observed between ST131 and any par-
ticular hospital.
Characteristics associated with ESBL-EC bloodstream
infection on univariable analysis included having a high
prevalence country of origin (Table 2). Patients with
ESBL-EC were also more likely to have community ac-
quired disease or chronic pulmonary disease, but were less
likely to have been recently admitted to ICU or Hospital 2
and were less likely to have had a previous transplant. For
ESBL-EC, the underlying source of bacteraemia was more
likely to be related to prostate biopsy but less likely to be
associated with febrile neutropaenia or central line infec-
tion. Several of these associations remained significant on
multivariate analysis (Table 2). Because only 51% of eli-
gible cases were included from Hospital 3, the multi-
variate analysis was repeated with Hospital 3 cases
excluded in order to evaluate the possibility that incom-
plete data may biased our findings. When taking this
approach, all variables found to be significant in the pri-
mary analysis remained significant with the exception of
previous transplant (data not shown).
Discussion
Our findings demonstrate that even when CTX-M is
predominant in both species, patients with bacteraemia
due to E. coli and K. pneumoniae have substantially dif-
ferent risk profiles. In addition, several findings suggest
that these differences are explained by underlying differ-
ences in transmission dynamics between species. Firstly,
the higher rate of community acquisition among ESBL-
EC indicates that community transmission plays a more
important role for ESBL-EC than ESBL-KP. This notion
is supported by the observation that ESBL-EC had more
diverse pulsed field patterns and resistance gene profiles,
consistent with more distant epidemiological linkage be-
tween isolates. Previous surveys describe similar differ-
ences in clonal diversity between these two species[20,21]. Furthermore, we observed no association be-
tween any particular hospital and ST131 whereas ESBL-
KP in general was associated with Hospital 2 and spe-
cific hospitals were associated with specific sequence
types, including ST-48. Of note, ST-48 is a widely dis-
seminated international clone that has been described in
the literature as a cause of hospital outbreaks [22,23].
Secondly, we found patients with ESBL-EC were more
likely to come from high prevalence countries. Although
country of origin has been highlighted previously as a risk
factor for ESBL-EC compared to susceptible E. coli, our
findings suggest that having a high prevalence country of
origin is more strongly associated with ESBL-EC than for
ESBL-KP. Possible explanations for this include higher
rates of acquisition of ESBL-EC during travel to high
prevalence regions, either by the patients themselves or
household members [24,25]. Either way, this observation
further supports the notion that ESBL-EC is more likely
than ESBL-KP to be acquired in community settings.
In contrast, we found that ESBL-KP was associated with
recent ICU admission and previous transplantation which
may be explained by ESBL-KP having higher rates of
transmission in the ICU or transplant ward setting [26,27].
Several other recent studies also found that ESBL-KP has
higher rates of transmission in healthcare settings, sug-
gesting that the inter-species differences in epidemiology
we describe are not unique to our region [26-29]. The rea-
son for these inter-species differences in transmissibility is
not well understood although recent work suggests that
differences in rates of environmental contamination with
viable organisms may be part of the explanation [30].
We also found that while the overall range of infections
caused by the two species was similar, ESBL-KP was associ-
ated with febrile neutropenia and central line infections
whereas ESBL-EC was associated with infections following
prostatic biopsy. The explanation for these observations are
uncertain but contributing factors may also include under-
lying differences in transmission dynamics since patients
with febrile neutropaenia and central line infections typic-
ally have more previous healthcare exposure than patients
with bacteraemia following an outpatient prostate biopsy.
Unexpectedly, we found an independent association
between ESBL-EC and chronic pulmonary disease. Simi-
lar findings have been reported previously. Another study
performed in the Auckland region, comparing ESBL-EC
to susceptible E. coli, also found an independent associ-
ation between ESBL-EC and chronic obstructive pulmon-
ary disease [31]. Another large multicentre Spanish study
also found chronic obstructive pulmonary disease to be an
independent risk factor for ESBL-EC [32]. Further investi-
gation is necessary to determine whether this observation
is due to a type 1 error, unmeasured confounding factors
or underlying causal mechanisms that are yet to be
characterized.
Table 2 Adjusted and unadjusted odds ratios with ESBL-EC bacteraemia as the dependent variable
ESBL-EC (%) ESBL-KP (%) Crude OR (95% CI)d/P value Adjusted OR (95% CI)d
Demographics/acquisition
Male gendera 60/92 (65.2) 49/78 (62.8) 1.1 (0.6–2.2)
Median age (IQR)a 65.5 (53–76) 61.5 (38.5-75.5) P = 0.01
High prevalence countrya 35/92 (38.0) 8/78 (10.3) 5.4 (2.2–13.7) 4.3 (1.6–11.6)
Pacific Islander 10/92 (10.9) 14/78 (17.9) 0.6 (0.2–1.4)
NZ Maori 2/92 (2.2) 6/78 (7.7) 0.3 (0.04–1.5)
LTCF residence 11/92 (12.0) 8/78 (10.3) 1.2 (0.4–3.5)
Community acquisitiona 35/92 (38.0) 6/78 (7.7) 7.4 (2.7–21.1) 7.9 (2.6–23.9)
Community onset infection 73/92 (79.3) 37/78 (47.4) 4.3 (2.1–8.8)
Recent ICU admissiona 5/92 (5.4) 14/78 (17.9) 0.3 (0.08–0.8)
Median hospital days (IQR) 1.5 (0–16) 9.5 (0–30.5) P <0.0001
Hospital 1a 53/92 (57.6) 29/78 (37.1) 2.3 (1.2–4.5)
Hospital 2a 21/92 (22.8) 32/78 (41.0) 0.4 (0.2–0.9) 0.3 (0.1–0.7)
Hospital 3a 18/92 (19.6) 17/78 (21.8) 0.9 (0.4–2.0)
Source of bacteraemia
Urinary tract 49/92 (53.3) 33/78 (42.3) 1.6 (0.8–3.0)
Gastrointestinal 17/92 (18.5) 10/78 (12.8) 1.5 (0.6–3.9)
Central line 0/92 (1.1) 5/78 (7.7) P = 0.02
Febrile neutropenia 6/92 (5.4) 13/78 (15.4) 0.3 (0.1–1.1)
Prostate biopsy related 8/92 (8.7) 0/78 (0) P = 0.008
Bone and joint 0/92 (0) 3/78 (3.8) P = 0.095
Respiratory tract 6/92(6.5) 3/78 (3.8) 1.7 (0.4–9.2)
Uncertainc 4/92 (4.3) 9/78 (11.5) 0.3 (0.1–1.3)
Comorbidities
Diabetes 22/92 (23.9) 14/78 (17.9) 1.4 (0.6–3.3)
Recurrent UTI 4/92 (4.3) 5/78 (6.4) 0.7 (0.1–3.0)
Long term IDC 11/92 (12.0) 12/78 (15.4) 0.7 (0.3–2.0)
Solid tumour 17/92 (18.5) 13/78 (16.7) 1.1 (0.5–2.7)
Haematological malignancy 12/92 (13.0) 16/78 (20.5) 0.6 (0.2–1.4)
Previous transplanta,b 1/92 (1.1) 7/78 (9.0) 0.1 (0.005–0.9) 0.06 (0.007–0.6)
Dialysis 4/92 (4.3) 2/78 (2.6) 1.7 (0.3–14.0)
CPDa 14/92 (15.2) 4/78 (5.1) 3.3 (1.0–12.6) 5.5 (1.5–20.1)
Median number comorbidities (IQR) 1 (1–3) 1 (1–2) P = 0.39
aIndicates that variable was included in the multivariate analysis.
b4 patients with liver transplants, and 4 patients with hematopoietic stem cell transplants transplants (one additional patient with a liver transplant had separate
episodes of ESBL-EC and ESBL-KP bacteremia).
cUncertain sources were those where the treating clinician was unable determine the aetiology.
dP values are included in this column for continuous variables and dichotomous variables for which an OR could not be calculated.
IQR, interquartile range; LTCF, long term care facility; UTI, urinary tract infection; IDC, Indwelling urinary catheter; CPD, Chronic pulmonary disease.
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we found to be associated with high rates of resistance to
ciprofloxacin, Hospital 2 and high rates of bacteraemia
among neutropaenic patients. More work is needed to de-
termine the geographic distribution of this clone and its
importance as a healthcare-associated pathogen.
Limitations of our study include retrospective data col-
lection and lack of information on antibiotic exposureand travel history as well as the exclusion of a number of
patients with no isolate available. Further limitations in-
clude the case-case study design, which does not allow for
identification of risk factors common to both organisms;
the inclusion of bacteraemic patients only, which limits
the applicability of our findings to other infections; and
the use of PFGE and MLST which compared to whole
genome sequencing, provide less information about the
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of the study include the inclusion of data from all acute
care hospitals in the region; the availability of comprehen-
sive and dependable data on previous hospital admissions
in the region; the molecular characterization of all isolates,
and the current lack of published data describing epi-
demiological differences between ESBL-EC and ESBL-KP.
Our findings also suggest that studies investigating risk
factors for ESBL-E may fail to detect relevant associations
if both species are combined as a single “case group”.
Moreover, recognized risk factors should not be assumed
to apply equally to both species. As studies are performed
on other important emerging resistance mechanisms in
Enterobacteriaceae such as NDM and KPC, these meth-
odological considerations are worth noting.
Conclusion
Our findings demonstrate that even when CTX-M is
predominant in both species, the epidemiological risk
profiles of patients with ESBL-EC and ESBL-KP are sub-
stantially different. Although further studies are needed,
this seems to be largely explained by differences between
the two species in terms of their propensity to transmit
in community and healthcare settings. Further work is
needed to determine the biological basis for these differ-
ences. As further insights are gained, new opportunities
will arise to expand and refine our repertoire of strat-
egies to prevent transmission of these organisms in both
community and healthcare settings. In the interim, our
findings imply that a single set of hospital infection con-
trol measures is unlikely to be equally effective against
both species and that tailored approaches to infection
control according to ESBL species may be helpful in
some instances.
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